New shot aims to shield babies from dangerous RSV
NCT ID NCT07109297
Summary
This study is checking the safety and real-world effectiveness of a single shot called nirsevimab, which is designed to protect against severe Respiratory Syncytial Virus (RSV). It will enroll about 110 babies and young children up to 24 months old who are at risk during RSV season. Researchers will follow the children for six months after the shot to see if it prevents serious lung infections and hospital visits.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number : 3560001
RECRUITINGNew Delhi, 110060, India
-
Investigational Site Number : 3560002
RECRUITINGBengaluru, 560011, India
-
Investigational Site Number : 3560003
RECRUITINGKolkata, 700017, India
-
Investigational Site Number : 3560004
ACTIVE_NOT_RECRUITINGPune, 411007, India
-
Investigational Site Number : 3560006
RECRUITINGVizianagaram, 535003, India
-
Investigational Site Number : 3560007
RECRUITINGNagpur, 441108, India
-
Investigational Site Number : 3560008
ACTIVE_NOT_RECRUITINGJaipur, 302007, India
Conditions
Explore the condition pages connected to this study.